Open Daily: 10am - 10pm | Alley door pickup 10am - 7pm 3038 Hennepin Ave Minneapolis, MN
612-822-4611

  • Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Phosphodiesterases as Drug Targets

Phosphodiesterases as Drug Targets

Francis, Sharron H.
Conti, Marco
Houslay, Miles D.

Paperback

Series: Handbook of Experimental Pharmacology, Book 204

Medical ReferenceChemistry

ISBN10: 3642269451
ISBN13: 9783642269455
Publisher: Springer Nature
Published: Nov 26 2013
Pages: 522
Weight: 1.65
Height: 1.09 Width: 6.14 Depth: 9.21
Language: English
Phosphodiesterase inhibitors: History of pharmacology; PDE inhibitors: factors that influence potency, selectivity and action; A fission yeast-based platform for phosphodiesterase inhibitor high throughput screening and analyses of phosphodiesterase activity; The pharmacokinetics of PDE inhibitors and the impact of this on their efficacy and the therapeutic window; Structural insight into the substrate specificity of phosphodiesterases; The GAF-tandem domain of phosphodiesterase 5 as a potential drug target; Small molecule allosteric modulators of phosphodiesterase 4; PDE 2 holoenzyme-insights about full length PDE and mechanism of activation by cGMP binding; Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases with dual-selective phosphodiesterase inhibitors and novel combination therapies; PDE inhibitors in the treatment of inflammatory diseases; Cyclic nucleotides and phosphodiesterases in monocyte differentiation; PDEs as targets for modulating T cell responses; Role of PDEs in adult-onset pulmonary arterial hypertension; Phosphodiesterases: emerging therapeutic targets for neonatal pulmonary hypertension; Phosphodiesterase inhibition in heart failure Evaluation of the Therapeutic Utility of Phosphodiesterase 5A Inhibition in the mdx Mouse Model of Duchenne Muscular Dystrophy; PDEs as targets for intermittent claudication; Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors; Regulation of endothelial barrier function by cyclic nucleotides: the role of phosphodiesterases; Potential use of PDE inhibitors in treatment of depression and improvement of cognition; PDEs as targets for the treatment of basal ganglia disorders Therapeutic potential of PDE inhibitors in parasitic diseases

Also in

Medical Reference

View All